Establishing the standards in biomarkers research - new white paper
May 2008
Biomarkers have the potential to encourage innovation, improve efficiency, and gain research organizations an advantage over their competitors. There seems little doubt that they will be one of the major drivers of pharmaceutical research and drug development in the 21st Century. In this new white paper, Thomson Reuters shows how the pharmaceutical industry is already beginning to rely on this information, and explains how important it is to establish the standards that will support increasing biomarker implementation in the future.
Biomarkers have the potential to encourage innovation, improve efficiency, save costs, and gain research organizations a valuable advantage over their competitors. Increasingly, decision makers throughout the development pipeline will turn to biomarker evidence to support their stage gate judgments, and patients will benefit from drugs that are more efficacious and have fewer side effects. However research organizations face a number of hurdles in realizing these benefits due to the lack of trustworthy biomarkers data and standards in the public domain.
By drawing on the experience and knowledge of scientists in Prous Science, a Thomson business, as well as extensive participation by key stakeholders, Thomson Scientific is uniquely placed to establish and develop these standards, and to provide trusted, authoritative biomarker information.
Establishing the Standards in Biomarker Research: download the complementary white paper
Additional information
Was this article useful?
Register now for KnowledgeLink, our customizable email newsletter that delivers expert insight on:
- Global innovation
- Information professional development
- Intellectual property
- Pharmaceutical knowledge
- Scientific research